Attached files
file | filename |
---|---|
EX-32.2 - EX-32.2 - Arcus Biosciences, Inc. | rcus-ex322_135.htm |
EX-31.2 - EX-31.2 - Arcus Biosciences, Inc. | rcus-ex312_137.htm |
EX-31.1 - EX-31.1 - Arcus Biosciences, Inc. | rcus-ex311_138.htm |
EX-23.1 - EX-23.1 - Arcus Biosciences, Inc. | rcus-ex231_139.htm |
EX-21.1 - EX-21.1 - Arcus Biosciences, Inc. | rcus-ex211_22.htm |
EX-10.37 - EX-10.37 - Arcus Biosciences, Inc. | rcus-ex1037_348.htm |
EX-10.36 - EX-10.36 - Arcus Biosciences, Inc. | rcus-ex1036_349.htm |
EX-10.35 - EX-10.35 - Arcus Biosciences, Inc. | rcus-ex1035_379.htm |
EX-10.22 - EX-10.22 - Arcus Biosciences, Inc. | rcus-ex1022_380.htm |
EX-4.3 - EX-4.3 - Arcus Biosciences, Inc. | rcus-ex43_381.htm |
10-K - 10-K - Arcus Biosciences, Inc. | rcus-10k_20201231.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Arcus Biosciences, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
|
(1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
Date: February 24, 2021 |
By: |
|
/s/ Terry Rosen |
|
|
|
Terry Rosen, Ph.D. |
|
|
|
Chief Executive Officer (Principal Executive Officer) |